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Abstract
As tumors continue to grow and exceed their blood supply, nutrients become limited leading to deficiencies in
amino acids (AAD), glucose (GD), and oxygen (hypoxia). These alterations result in significant changes in gene
expression. While tumors have been shown to overcome the stress associated with GD or hypoxia by stimulating
vascular endothelial growth factor (VEGF)–mediated angiogenesis, the role of AAD in tumor angiogenesis remains
to be elucidated. We found that in human tumors, the expression of the general control non-derepressible 2
(GCN2, an AAD sensor) kinase is elevated at both protein and mRNA levels. In vitro studies revealed that VEGF
expression is universally induced by AAD treatment in all five cell lines tested (five of five). This is in contrast to two
other angiogenesis mediators interleukin-6 (two of five) and fibroblast growth factor 2 (two of five) that have a more
restricted expression. Suppressing GCN2 expression significantly decreased AAD-induced VEGF expression. Si-
lencing activating transcription factor 4 (ATF4), a downstream transcription factor of the GCN2 signaling pathway,
is also associated with strong inhibition of AAD-induced VEGF expression. PKR-like kinase, the key player in GD-
induced unfolded protein response is not involved in this process. In vivo xenograft tumor studies in nonobese
diabetic/severe combined immunodeficient mice confirmed that knockdown of GCN2 in tumor cells retards tumor
growth and decreases tumor blood vessel density. Our results reveal that the GCN2/ATF4 pathway promotes tumor
growth and angiogenesis through AAD-mediated VEGF expression and, thus, is a potential target in cancer therapy.
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Introduction
As the blood supply of tumors becomes limited, the demand for
oxygen and nutrients such as glucose and amino acids increases
accordingly [1–4]. To ensure their survival, tumor cells have devel-
oped several strategies to overcome environmental stress. One adap-
tive mechanism applied by tumors is to reestablish their blood supply
by initiating the angiogenic switch. In this setting, proangiogenic
mediators are produced with a concomitant reduction of angiogenesis
inhibitors [3,5,6].
The eukaryotic translation initiation factor 2α (eIF-2α) can be phos-
phorylated by four different kinases in response to distinct stressors
[7,8]. The ER PKR-like kinase (PERK) and general control non-
derepressible 2 (GCN2) are generally activated in the ischemic tumor
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microenvironment [4,9,10]. ER stress caused by stressors such as glu-
cose deprivation (GD) activates PERK [6,11], while GCN2 is activated
by the direct binding of uncharged tRNAs that accumulate during
amino acid deprivation (AAD) [8,12,13]. Once activated, GCN2 phos-
phorylates eIF-2α at serine 51 resulting in reduced protein translation
[14–17], whereas translation of several mRNAs including activating
transcription factor 4 (ATF4) is upregulated. ATF4 then activates the
transcription of genes encoding amino acid biosynthetic enzymes and
genes involved in metabolism [18–21].
We and others have shown that ATF4 can regulate VEGF expression
by directly binding to its promoter [6,22,23]. We also demonstrated
that GD, a common environmental stressor, induces the angiogenic
switch in tumors through activation of the PERK/ATF4 pathway,
resulting in enhanced tumor angiogenesis [6]. However, studies inves-
tigating the role of AAD in tumor angiogenesis are limited and con-
flicting reports exist regarding the effect of AAD on the production
of proangiogenic mediators [3,24]. We hypothesized that as an adaptive
response toAAD, tumor cells could increase VEGFproduction to enhance
angiogenesis and in turn sustain tumor growth and progression.
Here, we demonstrate that VEGF expression is markedly increased
in response to AAD through activation of the GCN2/ATF4 pathway
in vitro. This is supported by the observation that GCN2 knock-
down in tumor cells results in impaired tumor growth and angiogenesis
in vivo. To our knowledge, there have been no previous reports impli-
cating GCN2 in VEGF regulation and tumor angiogenesis.
Materials and Methods
Cell Lines
The human head and neck squamous cell carcinoma (HNSCC)
cell lines UM-SCC-22B, UM-SCC-17B, and UM-SCC-81B (from
Dr Thomas E. Carey, Departments of Otorhinolaryngology and
Pharmacology, University of Michigan Medical School, Ann Arbor,
MI), the breast cancer cell line MCF7 (American Type Culture
Collection, Manassas, VA), the glioblastoma cell line U251 (from
Dr Yi Sun, Department of Radiation Oncology, University of
Michigan, AnnArbor,MI), andmouse embryonic fibroblast (MEF) cell
lines (MEF-PERK+/+ and MEF-PERK−/−, from Dr Andrew Fribley,
Department of Pediatrics, Division of Hematology/Oncology, Wayne
State University, Detroit, MI) were maintained in Dulbecco’s modified
eagle’s medium (DME) with high glucose (Invitrogen, Carlsbad, CA)
and 10% FBS. For AAD studies, amino acid–deficient and control
media from Sigma (St Louis, MO) were used (Catalog Nos D9443
and D6046, respectively), and final glucose concentration was adjusted
to 25 mM for both media. The AAD medium was also supplemented
with sodium pyruvate to match the control medium. All tumor cell
lines were authenticated by DNA fingerprinting with small tandem
repeat profiling.
Immunohistochemical Analysis
Immunohistochemistry (IHC) was performed as described previ-
ously [25]. Antibodies against GCN2 (Cell Signaling Technology,
Boston, MA) and CD31 (BD Pharmingen, San Jose, CA) were used.
The polink-1 HRP kit with 3-amino-9-ethylcarbazole chromogen
was employed for IHC staining. Tumor samples were obtained from
the University of Michigan School of Dentistry tissue core; normal
human oral mucosa (NHM; from Dr Hector Rios, Department of
Periodontics and Oral Medicine, University of Michigan School of
Dentistry, Ann Arbor, MI) was used as control. All imaging was done
using a Leica DM5000 microscope.
Laser Capture Microdissection
Laser capture microdissection (LCM) was performed as previously
described [26]. Approximately 100,000 epithelial cells from either
HNSCC or NHM were collected using a pulsed 337-nm UV laser.
RNA from at least nine independent tumors and eight NHM tissues
were pooled, respectively, and analyzed using real-time quantitative
polymerase chain reaction (qPCR).
Immunoblot analysis
Immunoblot analysis was done as previously described [6]. The
following primary antibodies were used: ATF4, β-actin (Santa Cruz
Biotechnology, Dallas, TX), PERK, and GCN2 (Cell Signaling
Technology). HRP-conjugated secondary antibodies were from
Santa Cruz Biotechnology. SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific, Rockford, IL) was used to visualize
immunoreactive bands.
Enzyme-Linked Immunosorbent Assay
ELISA was performed according to the manufacturer’s instruc-
tions. Briefly, cell culture supernatants were diluted 1:8 for VEGF,
1:4 for fibroblast growth factor 2 (FGF2), and 1:40 for interleukin-6
(IL-6) and applied to each well (100 μl), then incubated at room
temperature for 2 hours and washed three times. The secondary
antibody reaction was performed at room temperature (1 hour).
Stabilized chromogen was used for colorimetric reactions. Optical
density was measured at 450 nm using a plate reader (Spectra Max
M2; Molecular Devices Corporation, Sunnyvale, CA).
Lentivirus Infection
Green fluorescent protein (GFP)-expressing lentiviral constructs
expressing short hairpin RNA (shRNA) against GCN2, PERK, and
ATF4 were from Open Biosystems (Carlsbad, CA). For infection, 1 ×
105 cells were plated onto 6-cm plates, infected with the lentivirus,
and screened with puromycin (5 μg/ml) to remove non-infected cells.
Established stable cell lines were cultured with 2 μg/ml puromycin.
Real-time PCR
Total mRNA was extracted from cultured cells with EZ tissue/cell
total RNA mini kit (EZ BioResearch, St Louis, MO) following man-
ufacturer’s instructions. cDNA was synthesized using the Verso cDNA
kit (Thermo Scientific). Real-time PCR was performed in 384-well
plate with the ABI PRISM 7900HT Sequence Detection System.
Primers used for qPCR (18S rRNA, VEGF, and GCN2) were from
Applied Biosystems (Carlsbad, CA).
Tumor Growth and Angiogenesis In Vivo
Tumor cells (UM-SCC-22B-scshRNA and UM-SCC-22B-
shGCN2, 5 × 106) were injected subcutaneously in the flanks of
nonobese diabetic/severe combined immunodeficient (SCID) mice
(Harlan Laboratories, Haslett, MI). Tumor volume was measured
with a digital caliper every 2 days from day 10 post-injection. Tumor
volumes were calculated using the formula volume (mm3) = length ×
width2/2. At the end point, tumors were surgically removed and
measured, and angiogenesis was quantitated microscopically. This
study was carried out in strict accordance with the recommendations
in the Guide for the Care and Use of Laboratory Animals of the
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National Institutes of Health. The protocol was approved by the
University Committee on Use and Care of Animals (UCUCA) of
the University of Michigan (Animal Protocol No. 10283-1).
Statistical Analysis
Data are expressed as means ± SD and analyzed using unpaired two-
tailed Students’ t test. A value of P < .05 was considered to be significant.
Results
Expression of GCN2 Is Elevated in Human Tumors
Tumor cells are frequently subjected to glucose and AAD [3]. As a
result, metabolic adaptation is required to cope with episodes of
nutrient deprivation. GCN2, a sensor of AAD, plays a key role in yeast
and mammals in modulating amino acid metabolism in response to
nutrient deprivation [27]. It is well established that tumor cells respond
to GD by activating the unfolded protein response (UPR), which in
turn modulates tumor angiogenesis by activating the angiogenic switch
[6]. In HNSCCs, we found that GCN2 expression was significantly
increased (43.1%) compared to expression levels in normal human
mucosa (NHM, 3.7%; Figure 1A), suggesting a role for GCN2 in
tumorigenesis. Using LCM, epithelial cells from both HNSCC (nine
patients) and NHM (eight controls; Figure 1C ) were collected, and
qPCR was carried out to determine relative expression levels of
GCN2. A significant increase in GCN2 mRNA was observed in
HNSCC (Figure 1D), indicating AAD-induced tumor stress. We have
recently reported that GD is associated with increase of the two pro-
angiogenic mediators, IL-6 and VEGF. However, in human tumors
where GD and AAD occur simultaneously, the extent to which
ADD contributes to GCN2-mediated expression of these mediators
remains to be determined.
AAD Universally Induces VEGF Expression in
Human Tumors of Different Lineages
Figure 1 shows that GCN2 is upregulated in HNSCC. We have
previously shown that the proangiogenic mediators, IL-6 and VEGF,
are increased in human tumors and that UPR induced by GD was
responsible for the increased expression of these proangiogenic medi-
ators. Since AAD-induced VEGF mRNA expression has already
been reported [3,24], it is possible that AAD can also contribute
to expression of these proangiogenic mediators through activation
of GCN2. To clarify this relationship, the human oral squamous car-
cinoma cell line UM-SCC-22B was grown in AAD conditions from
1 to 24 hours. The AAD medium lacks the three amino acids arginine,
lysine, and leucine. Final glucose concentration in both the amino
acid–deficient and control media was adjusted to 25 mM. Real-time
PCR was performed to evaluate VEGF expression. As shown in Fig-
ure 2A, AAD induces VEGF expression in a time-dependent manner.
Figure 1. GCN2 is upregulated in human oral squamous cell carcinoma. (A) IHC staining of GCN2 in human oral squamous cell carci-
noma tissue and normal human mucosa. (B) Quantification showing percentage of GCN2-positive cells. (C) Epithelial cells were collected
using LCM fromNHM (eight samples, pooled) and HNSCC (nine samples, pooled). (D) qPCRwas used to analyze the expression of GCN2.
Gene expression levels in tumor tissues were normalized to their expression in normal mucosa (defined as 1). All photos were taken at
×100 magnification. Scale bar, 25 μm. *P < .05.
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To eliminate the possibility of a cell-specific response and to confirm
that VEGF expression is AAD-induced, the human glioblastoma cell
line U251, the breast cancer cell line MCF7, and two other oral squa-
mous cell carcinoma cell lines UM-SCC-17B and UM-SCC-81B were
grown in AAD conditions and VEGF expression was assessed. Tumor
cells cultured in GD conditions were used as a positive control. As
shown in Figure 2B, AAD induced VEGF expression at mRNA level
in all of the cell lines tested, indicating that AAD-induced VEGF
expression is a universal phenomenon in human tumors.
ELISA was performed to assess the production of VEGF in the
supernatant of AAD-treated cells (Figure 2C ). We found significant
increase in secreted VEGF under AAD treatment. Interestingly, the
expression of VEGF induced by GD or AAD was comparable (Fig-
ure 2, B and C ). Additionally, we investigated the effect of AAD on
the expression of two other well-known proangiogenic mediators IL-6
(Figure 2D) and FGF2 (Figure 2E ) in different cancer cell lines. As
seen, the response of IL-6 and FGF2 to AAD appears to be cell line–
specific. We therefore focus on AAD-induced VEGF expression
throughout this study. Collectively, these data indicate that AAD
plays an important role in differential regulation of angiogenesis
mediators in tumor cells regardless of their origin.
AAD-induced VEGF Expression Is Regulated by GCN2
Given that GCN2 is a sensor of AAD, its expression is increased in
tumors, and that AAD has been linked to the up-regulation of
VEGF, it is plausible that GCN2 contributes to AAD-induced
VEGF expression. To test this hypothesis, we used shRNA to sup-
press GCN2 in UM-SCC-22B cells and established two stable cell
lines UM-SCC-22B-shGCN2-1 and UM-SCC-22B-shGCN2-2.
High levels of knockdown efficiency were achieved for both
shGCN2-1 (95%) and shGCN2-2 (90%). Under AAD treatment,
GCN2 is upregulated and phosphorylated (upward shift of bands),
but the increase of GCN2 in GCN2 knockdown cell lines is minimal
(Figure 3A). Knocking down GCN2 significantly inhibits the expres-
sion of VEGF induced by AAD (Figure 3B). These results indicate
that GCN2 is essential for AAD-mediated VEGF expression.
AAD-induced VEGF Expression Is PERK-Independent
Previously, we have shown that the PERK pathway of the UPR is
activated under conditions of GD and regulates VEGF expression
through ATF4 [6]. Here, we found that AAD is able to promote
the expression of both ATF4 and spliced XBP1, suggesting a possible
activation of UPR (data not shown). We therefore wanted to inves-
tigate whether VEGF up-regulation that occurs with AAD is PERK-
dependent. PERK was knocked down in UM-SCC-22B cells using
shRNA generating two stable cell lines UM-SCC-22B-shPERK1 and
UM-SCC-22B-shPERK2. The established cell lines were grown under
conditions of GD or AAD, followed by assessment of their VEGF
expression (Figure 4). As shown in Figure 4A, we were able to achieve
significant knockdown efficiency. However, PERK knockdown was
Figure 2. AAD induces VEGF expression in multiple human tumors. (A) Time course study of UM-SCC-22B cells treated with AAD
medium (1-24 hours). qPCR revealed a time-dependent change of VEGF expression. (B) qPCR to determine VEGF expression in all five
cell lines during untreated, amino acid–deprived, or glucose-deprived conditions for 8 hours. (C–E) ELISA results showing VEGF, IL-6,
and FGF2 secretion levels for cell lines indicated during AAD or GD (8 hours). *P < .05.
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Figure 3. GCN2 plays a key role in AAD-induced VEGF expression. (A) UM-SCC-22B cells were infected with shRNA against GCN2
(shGCN2-1 and shGCN2-2) or scrambled shRNA (scshRNA) and treated with AAD or GD for 8 hours. GCN2 and ATF4 were detected
by Western blot (left panel). Percentage of GCN2 knockdown efficiency was quantified with ImageJ (right panel). (B) VEGF mRNA levels
were determined using qPCR (left). VEGF secretion was quantified with ELISA (right). *P < .05.
Figure 4. PERK is not involved in AAD-induced VEGF expression. (A) Stable cell lines 22B-scshRNA, 22B-shPERK1, and 22B-shPERK2
were established with lentiviral vectors and treated with AAD or GD for 8 hours. PERK and ATF4 expression was assessed with Western
blot (left). Percentage of PERK knockdown efficiency was quantified with ImageJ (right). (B) qPCR was performed to determine VEGF
expression in PERK knockdown cells under AAD or GD (left). ELISA shows secreted VEGF levels in the supernatant (right). (C) PERK and
ATF4 were analyzed by immunoblot in three cell lines, PERK+/+, PERK−/−, and rescued PERK knockout MEFs (mPERK) treated with
AAD or GD (left). qPCR results showing VEGF transcription levels in all three cell lines (right). *P < .05.
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unable to reduce ATF4 expression induced by AAD. In contrast,
knocking down PERK significantly reduced ATF4 expression induced
by GD.
Next, we examined VEGF transcription and secretion during both
AAD and GD in PERK knockdown cells. As seen in Figure 4B, both
VEGF transcription (left panel) and secretion (right panel ) remained
unchanged after AAD treatment, demonstrating that PERK is not
involved in VEGF expression on AAD. As an alternative approach,
we also used PERK−/−MEFs along with their wild-type counterparts
to study VEGF expression under AAD and GD (Figure 4C ). Similar
to our observations in UM-SCC-22B cells, PERK−/− MEFs were
still fully able to upregulate ATF4 under AAD, further demonstrat-
ing that PERK is not involved in ATF4 regulation during AAD
(Figure 4C , left panel ). VEGF expression also remained unchanged
in PERK−/− MEFs subjected to AAD (Figure 4C , right panel ). In
contrast, VEGF expression was markedly reduced with GD treatment
in PERK−/−MEFs. We also reintroduced mouse PERK (mPERK) in
the PERK−/− MEFs and found that ectopic expression of mPERK
increased VEGF expression in PERK−/− MEFs during GD but had
no effect on AAD-induced VEGF expression (Figure 4C ). Collec-
tively, our data exclude the participation of PERK in AAD-mediated
VEGF expression.
ATF4 Regulates AAD-Induced VEGF Expression
ATF4 regulates VEGF expression by binding to its promoter and
is also a common downstream target where the PERK and GCN2
pathways converge [6,22,23]. We found that suppressing GCN2
was able to inhibit AAD-induced ATF4 expression (Figure 3A).
To confirm the role of ATF4 in VEGF expression induced by
AAD, we knocked down ATF4 in UM-SCC-22B cells using lenti-
viral constructs and performed a time course analysis. Immunoblots
demonstrated a potent knockdown of ATF4 compared to the scram-
bled control (Figure 5A). We next investigated the effect of ATF4
knockdown on VEGF expression and secretion. As shown in
Figure 5B, the knockdown of ATF4 significantly inhibited VEGF
expression at both mRNA and protein levels demonstrating a critical
role for ATF4 in regulating AAD-mediated VEGF expression.
Inhibition of GCN2 Is Able to Inhibit Tumor Growth and
Blood Vessel Formation in a Xenograft Tumor Model
The role of GCN2 has been reported in tumor cell survival and
proliferation [4]. However, a role for GCN2 in angiogenesis has not
been reported. Investigating effects of GCN2 knockdown in vivo
using tumor xenografts in SCID mice can shed light on how GCN2
regulates tumor angiogenesis and growth. UM-SCC-22B-shGCN2-1
cells were injected subcutaneously into SCID mice flanks. UM-SCC-
22B-scshRNA cells were used as controls. Thirty days later, tumors
were harvested, photographed, and measured. As shown in Figure 6,
A and B, GCN2 knockdown in tumor cells significantly reduced tumor
volume and weight compared to the controls (P < .05). Blood vessels
were stained using CD31 antibody, and random photographs were
used for quantification. Blood vessel density was defined as number
of blood vessels per field. The results demonstrated a marked decrease
of blood vessel density in GCN2 knockdown tumors. To further con-
firm that GCN2 pathway is functionally impaired in our xenograft
model, tumor cells were collected using LCM and subjected to qPCR
analysis. The results show that GCN2 was efficiently knocked down,
and in turn, its downstream transcription factor ATF4 was inhibited.
VEGF expression level was also suppressed (Figure 6C ). The results
above suggest a critical role for GCN2 in regulating tumor blood vessel
growth in vivo.
Figure 5. ATF4 is involved in AAD-induced VEGF expression. Stable cell lines 22B-scshRNA and 22B-shATF4-9 were established with
lentiviral vectors and treated without (NT) or with AAD for 4, 8, and 12 hours. (A) ATF4 expression was assessed with Western blot (left)
showing a time-dependent trend. The relative density of ATF4 bands were measured and normalized to NT for all three time points
(right). (B) VEGF expression was quantified using qPCR for the 8- and 12-hour time points (left). (C) Secreted VEGF was measured using
ELISA for the 12-hour time point. *P < .05.
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Discussion
Growing tumors are often subjected to deficiencies in vital nutrients
and oxygen.We recently reported that GD contributes to tumor angio-
genesis by increasing expression of multiple proangiogenic factors
through the PERK/ATF4 pathway [6]. Although AAD-induced VEGF
expression has been reported, the results are conflicting. Drogat et al.
[24] reported that although glutamine deprivation potently induces
VEGF mRNA expression, it leads to the decrease of VEGF expression
at the protein level in A549/8 human carcinoma cells. In contrast,
Marjon and colleagues found that glutamine deprivation caused a
marked induction in both transcription and the secretion of VEGF
in a human breast adenocarcinoma cell line (TSE cells) [3]. To eluci-
date the effect of AAD on VEGF expression, we used tumor cell lines
from different lineages, including breast cancer, glioblastoma, and
oral squamous cell carcinomas, and studied the effect of AAD on
VEGF expression at both mRNA and protein levels. We found that
AAD promotes the expression of VEGF in all cell lines tested. The pro-
duction of VEGF induced by AAD suggests that AAD, a common
stressor in the tumor microenvironment, contributes, at least in part,
to tumor angiogenesis.
Although the phenomenon of AAD-induced VEGF expression has
been described before, the underlying mechanism remains unknown.
It is well established that GCN2 is a sensor of AAD and is able to
activate ATF4. Our previous work demonstrates that ATF4 is critical
in the regulation of proangiogenic mediators. We hypothesized that
AAD promotes VEGF expression to accelerate blood vessel forma-
tion through GCN2. Indeed, we found that GCN2 is overexpressed
in human tumors. In vitro data also showed that AAD could increase
Figure 6. Knockdown of GCN2 is sufficient to inhibit tumor growth and blood vessel formation in vivo. Stable cell lines 22B-scshRNA
and 22B-shGCN2-1 were injected subcutaneously into flanks of SCID mice. (A) Excised tumors derived from each cell line (left). Tumor
volume (middle panel) and tumor weight (right) were measured at the experiment end point. Tumors derived from 22B-shGCN2-1 cells
have smaller volumes and lower weight values. (B) Tumor microvessel density was assessed by IHC staining for the endothelial cell
marker CD31 (left), and the number of blood vessels per field was quantified (right). IgGwas used as negative control. *P< .05. (C) LCMwas
used to collect tumor cells from xenograft tumor samples and qPCR was used to determine expression levels of GCN2, ATF4, and VEGF.
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GCN2 expression and phosphorylation. shRNA-mediated silencing
of GCN2 inhibits AAD-induced ATF4 expression, a downstream
transcription factor. Not surprisingly, VEGF expression is signifi-
cantly inhibited by GCN2 knockdown. To confirm that ATF4 is
involved in AAD-mediated VEGF regulation, shRNA against
ATF4 was used to reduce its expression. On AAD treatment, VEGF
expression was inhibited at both mRNA and protein levels. These
results support the hypothesis that AAD induces VEGF expression
by activating the GCN2/ATF4 signaling pathway.
We observed that GD was able to promote accumulation of
GCN2 but not its phosphorylation (Figure 3). Additionally, we
found that GCN2 knockdown does not inhibit GD-induced VEGF
expression. It has been reported that when cells experience GD, they
use amino acids as a replacement energy supply to ensure their sur-
vival [4,10]. Thus, GD appears to contribute to AAD, which in turn
activates GCN2. If AAD induces VEGF through GCN2, suppres-
sing GCN2 should be able to inhibit GD-induced VEGF expression.
The observed conflict between our studies and the report by Ye and
colleagues [4] may be because GD does not cause secondary AAD
during early time points and cannot promote the phosphorylation
of GCN2. GD-induced VEGF expression may fully depend on
the PERK/ATF4 pathway of the UPR at 8 hours of treatment.
Therefore, GCN2 does not appear to play a role in GD-induced
expression of VEGF in this scenario. It would be interesting to know
if GCN2 is involved in GD-induced late-stage VEGF expression.
Jousse and colleagues showed that AAD does not activate the UPR
and regulates CHOP expression through a pathway that is indepen-
dent of the UPR [28]. It has also been reported that GD, and not
AAD, activates the UPR in human renal cortical tubular cells in culture
[29]. Interestingly, we observed XBP1-s bands in the samples from
AAD-treated tumor cells, suggesting possible activation of the UPR
by AAD. If so, then PERK should also be activated and be responsible
for the increase in ATF4. However, the phosphorylation of PERK was
never detected under AAD treatment, and suppressing PERK with
shRNA had no effect on AAD-induced VEGF expression, excluding
a role of UPR during AAD. It would be interesting to determine
how XBP1-s is activated by AAD, considering that that XBP-1s is
involved in expression of the inflammatory cytokine IL-6 [30,31] as
well as VEGF expression [32].
In summary, our studies show that the GCN2/ATF4 pathway is
involved in AAD-induced expression of proangiogenic mediators in
tumors. Suppressing GCN2 is able to partially inhibit tumor growth
and blood vessel formation in xenograft tumors grown in SCID
mice. We therefore propose a model (Figure 7) in which the tumor
microenvironment (TME) stressors GD and AAD each act through
distinct kinases (PERK and GCN2, respectively) to phosphorylate
eIF-2α, which in turn leads to reduced global translation with the
exception of select genes such as ATF4. Activation of GCN2, PERK,
and their downstream target ATF4 is central for tumors to adapt to
nutrient deprivation in the TME, eliciting gene expression that
Figure 7. Schematic model demonstrating the mechanisms by which stressors in the tumor microenvironment mediate angiogenesis.
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enhances tumor angiogenesis, thereby promoting tumor survival and
proliferation. Thus, ATF4 appears to be a promising target for anti-
angiogenic cancer therapy. Moreover, the emerging contribution of
environmental stress as a tumor-promoting factor is an important
consideration when designing targeted cancer therapies.
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